These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 29967165)

  • 1. Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance.
    Kirkman LA; Zhan W; Visone J; Dziedziech A; Singh PK; Fan H; Tong X; Bruzual I; Hara R; Kawasaki M; Imaeda T; Okamoto R; Sato K; Michino M; Alvaro EF; Guiang LF; Sanz L; Mota DJ; Govindasamy K; Wang R; Ling Y; Tumwebaze PK; Sukenick G; Shi L; Vendome J; Bhanot P; Rosenthal PJ; Aso K; Foley MA; Cooper RA; Kafsack B; Doggett JS; Nathan CF; Lin G
    Proc Natl Acad Sci U S A; 2018 Jul; 115(29):E6863-E6870. PubMed ID: 29967165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structures revealing mechanisms of resistance and collateral sensitivity of Plasmodium falciparum to proteasome inhibitors.
    Hsu HC; Li D; Zhan W; Ye J; Liu YJ; Leung A; Qin J; Crespo B; Gamo FJ; Zhang H; Cui L; Roth A; Kirkman LA; Li H; Lin G
    Nat Commun; 2023 Dec; 14(1):8302. PubMed ID: 38097652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of Asparagine Ethylenediamines as Anti-malarial
    Zhan W; Visone J; Ouellette T; Harris JC; Wang R; Zhang H; Singh PK; Ginn J; Sukenick G; Wong TT; Okoro JI; Scales RM; Tumwebaze PK; Rosenthal PJ; Kafsack BFC; Cooper RA; Meinke PT; Kirkman LA; Lin G
    J Med Chem; 2019 Jul; 62(13):6137-6145. PubMed ID: 31177777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Highly Selective Plasmodium falciparum Proteasome Inhibitor with Anti-malaria Activity in Humanized Mice.
    Zhan W; Zhang H; Ginn J; Leung A; Liu YJ; Michino M; Toita A; Okamoto R; Wong TT; Imaeda T; Hara R; Yukawa T; Chelebieva S; Tumwebaze PK; Lafuente-Monasterio MJ; Martinez-Martinez MS; Vendome J; Beuming T; Sato K; Aso K; Rosenthal PJ; Cooper RA; Meinke PT; Nathan CF; Kirkman LA; Lin G
    Angew Chem Int Ed Engl; 2021 Apr; 60(17):9279-9283. PubMed ID: 33433953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Covalent Plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents.
    Stokes BH; Yoo E; Murithi JM; Luth MR; Afanasyev P; da Fonseca PCA; Winzeler EA; Ng CL; Bogyo M; Fidock DA
    PLoS Pathog; 2019 Jun; 15(6):e1007722. PubMed ID: 31170268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitigating the risk of antimalarial resistance via covalent dual-subunit inhibition of the Plasmodium proteasome.
    Deni I; Stokes BH; Ward KE; Fairhurst KJ; Pasaje CFA; Yeo T; Akbar S; Park H; Muir R; Bick DS; Zhan W; Zhang H; Liu YJ; Ng CL; Kirkman LA; Almaliti J; Gould AE; Duffey M; O'Donoghue AJ; Uhlemann AC; Niles JC; da Fonseca PCA; Gerwick WH; Lin G; Bogyo M; Fidock DA
    Cell Chem Biol; 2023 May; 30(5):470-485.e6. PubMed ID: 36963402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of proteasome inhibitors with oral efficacy in vivo against
    Xie SC; Metcalfe RD; Mizutani H; Puhalovich T; Hanssen E; Morton CJ; Du Y; Dogovski C; Huang SC; Ciavarri J; Hales P; Griffin RJ; Cohen LH; Chuang BC; Wittlin S; Deni I; Yeo T; Ward KE; Barry DC; Liu B; Gillett DL; Crespo-Fernandez BF; Ottilie S; Mittal N; Churchyard A; Ferguson D; Aguiar ACC; Guido RVC; Baum J; Hanson KK; Winzeler EA; Gamo FJ; Fidock DA; Baud D; Parker MW; Brand S; Dick LR; Griffin MDW; Gould AE; Tilley L
    Proc Natl Acad Sci U S A; 2021 Sep; 118(39):. PubMed ID: 34548400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasmodium berghei K13 Mutations Mediate
    Simwela NV; Stokes BH; Aghabi D; Bogyo M; Fidock DA; Waters AP
    mBio; 2020 Nov; 11(6):. PubMed ID: 33173001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure- and function-based design of Plasmodium-selective proteasome inhibitors.
    Li H; O'Donoghue AJ; van der Linden WA; Xie SC; Yoo E; Foe IT; Tilley L; Craik CS; da Fonseca PC; Bogyo M
    Nature; 2016 Feb; 530(7589):233-6. PubMed ID: 26863983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibilities of Ugandan Plasmodium falciparum Isolates to Proteasome Inhibitors.
    Garg S; Kreutzfeld O; Chelebieva S; Tumwebaze PK; Byaruhanga O; Okitwi M; Orena S; Katairo T; Nsobya SL; Conrad MD; Aydemir O; Legac J; Gould AE; Bayles BR; Bailey JA; Duffey M; Lin G; Kirkman LA; Cooper RA; Rosenthal PJ
    Antimicrob Agents Chemother; 2022 Oct; 66(10):e0081722. PubMed ID: 36094216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemogenomic Profiling of a Plasmodium falciparum Transposon Mutant Library Reveals Shared Effects of Dihydroartemisinin and Bortezomib on Lipid Metabolism and Exported Proteins.
    Pires CV; Oberstaller J; Wang C; Casandra D; Zhang M; Chawla J; Adapa SR; Otto TD; Ferdig MT; Rayner JC; Jiang RHY; Adams JH
    Microbiol Spectr; 2023 Jun; 11(3):e0501422. PubMed ID: 37067430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome.
    Xie SC; Gillett DL; Spillman NJ; Tsu C; Luth MR; Ottilie S; Duffy S; Gould AE; Hales P; Seager BA; Charron CL; Bruzzese F; Yang X; Zhao X; Huang SC; Hutton CA; Burrows JN; Winzeler EA; Avery VM; Dick LR; Tilley L
    J Med Chem; 2018 Nov; 61(22):10053-10066. PubMed ID: 30373366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of potent and reversible piperidine carboxamides that are species-selective orally active proteasome inhibitors to treat malaria.
    Lawong A; Gahalawat S; Ray S; Ho N; Han Y; Ward KE; Deng X; Chen Z; Kumar A; Xing C; Hosangadi V; Fairhurst KJ; Tashiro K; Liszczak G; Shackleford DM; Katneni K; Chen G; Saunders J; Crighton E; Casas A; Robinson JJ; Imlay LS; Zhang X; Lemoff A; Zhao Z; Angulo-Barturen I; Jiménez-Díaz MB; Wittlin S; Campbell SF; Fidock DA; Laleu B; Charman SA; Ready JM; Phillips MA
    Cell Chem Biol; 2024 Aug; 31(8):1503-1517.e19. PubMed ID: 39084225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A small-molecule inhibitor of the DNA recombinase Rad51 from
    Vydyam P; Dutta D; Sutram N; Bhattacharyya S; Bhattacharyya MK
    J Biol Chem; 2019 May; 294(20):8171-8183. PubMed ID: 30936202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defining the Determinants of Specificity of Plasmodium Proteasome Inhibitors.
    Yoo E; Stokes BH; de Jong H; Vanaerschot M; Kumar T; Lawrence N; Njoroge M; Garcia A; Van der Westhuyzen R; Momper JD; Ng CL; Fidock DA; Bogyo M
    J Am Chem Soc; 2018 Sep; 140(36):11424-11437. PubMed ID: 30107725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Potent and Highly Selective Epoxyketone-Based Plasmodium Proteasome Inhibitors.
    Almaliti J; Fajtová P; Calla J; LaMonte GM; Feng M; Rocamora F; Ottilie S; Glukhov E; Boura E; Suhandynata RT; Momper JD; Gilson MK; Winzeler EA; Gerwick WH; O'Donoghue AJ
    Chemistry; 2023 Apr; 29(20):e202203958. PubMed ID: 36617500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Covalent Macrocyclic Proteasome Inhibitors Mitigate Resistance in
    Bennett JM; Ward KE; Muir RK; Kabeche S; Yoo E; Yeo T; Lam G; Zhang H; Almaliti J; Berger G; Faucher FF; Lin G; Gerwick WH; Yeh E; Fidock DA; Bogyo M
    ACS Infect Dis; 2023 Oct; 9(10):2036-2047. PubMed ID: 37712594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, Synthesis, and Optimization of Macrocyclic Peptides as Species-Selective Antimalaria Proteasome Inhibitors.
    Zhang H; Ginn J; Zhan W; Liu YJ; Leung A; Toita A; Okamoto R; Wong TT; Imaeda T; Hara R; Yukawa T; Michino M; Vendome J; Beuming T; Sato K; Aso K; Meinke PT; Nathan CF; Kirkman LA; Lin G
    J Med Chem; 2022 Jul; 65(13):9350-9375. PubMed ID: 35727231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-Activity Relationship Studies of Antimalarial
    Zhang H; Ginn J; Zhan W; Leung A; Liu YJ; Toita A; Okamoto R; Wong TT; Imaeda T; Hara R; Michino M; Yukawa T; Chelebieva S; Tumwebaze PK; Vendome J; Beuming T; Sato K; Aso K; Rosenthal PJ; Cooper RA; Liverton N; Foley M; Meinke PT; Nathan CF; Kirkman LA; Lin G
    J Med Chem; 2023 Jan; 66(2):1484-1508. PubMed ID: 36630286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a Potent Inhibitor of the Plasmodium Proteasome with Reduced Mammalian Toxicity.
    LaMonte GM; Almaliti J; Bibo-Verdugo B; Keller L; Zou BY; Yang J; Antonova-Koch Y; Orjuela-Sanchez P; Boyle CA; Vigil E; Wang L; Goldgof GM; Gerwick L; O'Donoghue AJ; Winzeler EA; Gerwick WH; Ottilie S
    J Med Chem; 2017 Aug; 60(15):6721-6732. PubMed ID: 28696697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.